Consensus Keros Therapeutics, Inc.

Stocks

KROS

US4923271013

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 21/10/2026 +03			5-day change	1st Jan Change
11.18 ^USD	-1.93%		+1.18%	-45.09%

09-29	Keros Therapeutics Expects $20 Million Milestone Payment From Takeda	MT
09-29	Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda	CI

Evolution of the Average Target: Keros Therapeutics, Inc.

Evolution of the Target Price: Keros Therapeutics, Inc.

Changes in Analyst Recommendations: Keros Therapeutics, Inc.

9b9b7359d37c5d0b6c515.dD0bMym_DGSFzUmfsmAgxCYykHZgrY626KuGUXJbcHI.TUhQd2DpPQK2tX_r6C14rnBXwx4p4NTlq5LJZkUTFjMkRGl9YdhrEbH6GA~60ab31453982ab0bdffd4ef6fad51bb7

Analysts' recommendations: Keros Therapeutics, Inc.

08-11	BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20	MT
11-12	Oppenheimer Adjusts Keros Therapeutics Price Target to $27 From $23, Maintains Outperform Rating	MT
11-06	Wedbush Raises Price Target on Keros Therapeutics to $16 From $15, Keeps Neutral Rating	MT
10/06/25	BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32	MT
09/04/25	Truist Cuts Price Target on Keros Therapeutics to $25 From $43, Keeps Buy Rating	MT
21/01/25	Cantor Fitzgerald Downgrades Keros Therapeutics to Neutral From Overweight	MT
17/01/25	Wedbush Downgrades Keros Therapeutics to Neutral From Outperform	MT
16/01/25	Oppenheimer Cuts Price Target on Keros Therapeutics to $23 From $63, Maintains Outperform Rating	MT
23/12/24	Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating	MT
16/12/24	Guggenheim Downgrades Keros Therapeutics to Neutral From Buy	MT
12/12/24	BTIG Downgrades Keros Therapeutics to Neutral From Buy; Shares Plunge	MT
12/12/24	TD Cowen Downgrades Keros Therapeutics to Hold From Buy	MT
12/12/24	William Blair Downgrades Keros Therapeutics to Market Perform From Outperform	MT
12/12/24	Wedbush Adjusts Price Target on Keros Therapeutics to $47 From $84, Keeps Outperform Rating	MT
24/10/24	Cantor Fitzgerald Initiates Keros Therapeutics at Overweight	MT
16/10/24	Scotiabank Initiates Keros Therapeutics at Sector Outperform	MT
23/09/24	Guggenheim Initiates Keros Therapeutics at Buy With $96 Price Target	MT
25/06/24	Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target	MT
31/07/23	Wedbush Starts Keros Therapeutics at Outperform With $86 Price Target	MT
26/07/23	BofA Securities Initiates Keros Therapeutics With Buy Rating, $65 Price Target	MT
26/07/23	BofA Securities Starts Keros Therapeutics at Buy With $65 Price Target	MT
05/05/23	Piper Sandler Adjusts Keros Therapeutics' Price Target to $110 From $120, Keeps Overweight Rating	MT
14/02/23	Cowen Starts Keros Therapeutics at Outperform	MT
13/12/22	BTIG Adjusts Price Target on Keros Therapeutics to $105 From $95, Maintains Buy Rating	MT
18/10/22	Truist Securities Starts Keros Therapeutics at Buy With $100 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	KEROS THERAPEUTICS, INC.					+77.4%
	WUXI APPTEC CO., LTD.					+30.22%
	ARGENX SE					+28.19%
	LONZA GROUP AG					+11.71%
	IQVIA HOLDINGS INC.					+9.41%
	BEONE MEDICINES AG					+12.94%
	REVOLUTION MEDICINES, INC.					+32.56%
	CELLTRION, INC.					+35.55%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.74%
	GENMAB A/S					+5.95%
	Average					+26.57%
	Weighted average by Cap.					+21.74%